849217-50-1 Usage
Chemical structure
The compound has a cyclopropane ring and a carboxamide group, with fluorine, hydroxy, methoxy, quinolinyl, and phenyl groups attached to it.
Potential pharmaceutical or biological activity
The presence of various functional groups suggests that the compound may have potential pharmaceutical or biological activity.
Structural features
The compound has structural features that are often found in bioactive molecules, which may contribute to its potential pharmaceutical or biological activity.
Further experimentation and analysis required
Further experimentation and analysis are needed to determine the specific properties and potential uses of this chemical.
Fluorine atoms
The compound contains two fluorine atoms, which may contribute to its reactivity and stability.
Hydroxy and methoxy groups
The presence of hydroxy and methoxy groups may affect the compound's solubility and reactivity.
Quinolinyl group
The quinolinyl group is a common structural feature in many bioactive molecules and may contribute to the compound's potential biological activity.
Phenyl groups
The presence of phenyl groups may affect the compound's lipophilicity and stability.
Carboxamide group
The carboxamide group may contribute to the compound's hydrogen bonding capacity and solubility in water.
Complex compound
The compound is a complex molecule with multiple functional groups, which may contribute to its potential pharmaceutical or biological activity.
Check Digit Verification of cas no
The CAS Registry Mumber 849217-50-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,9,2,1 and 7 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 849217-50:
(8*8)+(7*4)+(6*9)+(5*2)+(4*1)+(3*7)+(2*5)+(1*0)=191
191 % 10 = 1
So 849217-50-1 is a valid CAS Registry Number.
849217-50-1Relevant articles and documents
QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF
-
, (2022/02/19)
Provided is a quinolyl-containing compound as shown in general formula (I) or (II) or a pharmaceutically acceptable salt, a solvate, an active metabolite, a polymorph, an isotopic label, or an isomer thereof, and further provided are a pharmaceutical composition comprising the compound and use of the compound and the pharmaceutical composition. The provided compound has a dual molecule function, can serve as multi -target inhibitors of novel tyrosine kinase/histone deacetylase, can simultaneously achieve the effect of two inhibitors, has excellent biological activity and pharmacokinetic properties, and has the application potential particularly in the field of treatment of tumors.
Preparation methods of tyrosine kinase inhibitor XJF007 and its intermediate
-
, (2019/07/04)
The invention discloses preparation methods of tyrosine kinase inhibitor XJF007 with a general structural formula (I) and its intermediate. The preparation method of the tyrosine kinase inhibitor XJF007 employs a collecting synthesis strategy of construct
A alkyne generation quinoline derivatives and its preparation and use
-
, (2017/08/25)
The invention discloses alkynylquinoline derivatives, and a preparation method and application thereof. The acetylenoquinoline derivatives are alkynylquinoline compounds as shown in a general formula I which is described in the specification and pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof. The invention also provides the preparation method for the derivatives and relates to inhibition activity of the compounds as shown in the formula I to a variety of protein tyrosine kinases (e.g. C-Met and VEGFR). Thus, the compounds can be used as anticancer drugs for treatment of human cancers.
